Navigation Links
PAREXEL to Present Leading Insights Regarding Key Industry Topics at 20th Annual Drug Information Association EuroMeeting

BOSTON, Feb. 25 /PRNewswire-FirstCall/ -- Experts from PAREXEL International Corporation (Nasdaq: PRXL), a leading global bio/pharmaceutical services provider, will present on key topics at the Drug Information Association's (DIA) 20th Annual EuroMeeting in Barcelona, Spain being held March 3 - 5, 2008. Attendees will benefit from presentations by some of PAREXEL's thought leaders, selected by the DIA to address industry issues including pharmacovigilance, globalization of clinical trials, data-driven patient recruitment, non-interventional studies, gene therapy regulations, combination products, biosimilars, and cosmeceuticals.

PAREXEL experts will present or chair the following sessions:

Monday, March 3

-- Pharmacovigilance and Medical Writing View With Emphasis on Practical

Solutions to the Pitfalls and Grey Areas (tutorial) - Alison Rapley,

Director, Medical Writing Services, Europe, Clinical Research Services


-- Navigating the Gene Therapy Regulations for Clinical Trials -- Cecil

Nick, Principal Consultant, PAREXEL Consulting


Tuesday, March 4

-- Globalization of Clinical Trials: Opportunities and Risks -- Session

Chair: Alberto Grignolo, Ph.D., Corporate Vice President and General

Manager, PAREXEL Consulting


-- Combination Products: Drug or Device? -- Cecil Nick, Principal

Consultant, PAREXEL Consulting


-- Data Driven Patient Recruitment: Tools for Early Planning and

Predictive Management (poster presentation) -- Petra Moll, Associate

Director, Clinical Operations, Clinical Research Services

Wednesday, March 5

-- Meeting Patient Enrollment Targets for Non-Interventional Studies --

Gary Coward, Senior Director, Peri-Approval Clinical Excellence,

Clinical Research Services


-- Biosimilars: What Should the Next Steps Be? -- Session Co-Chair: Cecil

Nick, Principal Consultant, PAREXEL Consulting


-- Cosmeceuticals: Marketing Topical Products without Making Licensable

Medicinal Claims in Europe -- Peter Lassoff, Vice President, PAREXEL



For more than 25 years, clients have relied on PAREXEL to provide integrated clinical development, regulatory affairs consulting, and commercialization services, as well as to offer technologies that expedite time-to-market. Attendees at the DIA EuroMeeting can visit PAREXEL's Booth 179 in the exhibit hall to discuss these areas or to view a demonstration of the industry-leading Clinical Trial Management System IMPACT(R) software, provided by PAREXEL's subsidiary, Perceptive Informatics.

DIA's 20th Annual EuroMeeting is global in scope, attracting more than 3,000 attendees. This meeting brings together professionals from the biopharmaceutical industry, contract service organizations, academic research centers, and regulatory agencies. With more than 100 sessions and 11 themes, and more than 350 speakers, the annual event covers a variety of cross- disciplinary topics.

For more information about PAREXEL visit or Booth 179 at the DIA EuroMeeting.

About PAREXEL International

PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 64 locations throughout 51 countries around the world, and has more than 7,300 employees. For more information about PAREXEL International visit

This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the period ended December 31, 2007 as filed with the SEC on February 7, 2008, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements

should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL and IMPACT are registered trademarks of PAREXEL International Corporation, and PERCEPTIVE INFORMATICS is a registered trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of their respective business and are hereby acknowledged.


Jennifer Baird, Director of Public Relations

PAREXEL International

Tel: +781-434-4409


Rebecca Passo

SHIFT Communications

Tel: +617-779-1817


SOURCE PAREXEL International Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. PAREXEL International to Present at Thomas Weisel Partners Healthcare Conference
2. Parexel Consulting Strengthens Good Manufacturing Practice Capabilities in Europe
3. PAREXEL International Completes Acquisition of APEX International Clinical Research Co., Ltd.
4. PAREXEL International Updates Financial Guidance in Conjunction with the Acquisition of APEX International Clinical Research Co., Ltd. and Other Factors
5. PAREXEL Announces Date of First Quarter Fiscal Year 2008 Earnings Release and Conference Call
6. PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results
7. PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities
8. PAREXEL Announces Date of Second Quarter Fiscal Year 2008 Earnings Release and Conference Call
9. PAREXEL Names Biopharmaceutical Industry Executive Eduard E. Holdener to Board of Directors
10. PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results
11. PAREXEL International Announces 2-For-1 Stock Split
Post Your Comments:
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... While ... machines such as the Cary 5000 and the 6000i models are higher end machines ... is the height of the spectrophotometer’s light beam from the bottom of the cuvette ...
(Date:6/23/2016)... ... 23, 2016 , ... Mosio, a leader in clinical research ... Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the ... tools, and strategies for clinical researchers. , “The landscape of how patients receive ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... A person commits a crime, and the detective ... the criminal down. An outbreak of foodborne illness ... (FDA) uses DNA evidence to track down the bacteria that ... It,s not. The FDA has increasingly used a complex, cutting-edge ... illnesses. Put as simply as possible, whole genome sequencing is ...
Breaking Biology Technology:
(Date:4/28/2016)... and BANGALORE, India , April ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... today announced a global partnership that will provide ... to use mobile banking and payment services.      ... a key innovation area for financial services, but it also ...
(Date:4/15/2016)... -- A new partnership announced today will help life ... a fraction of the time it takes today, ... insurance policies to consumers without requiring inconvenient and ... rapid testing (A1C, Cotinine and HIV) and higi,s ... pulse, BMI, and activity data) available at local ...
(Date:3/31/2016)... March 31, 2016  Genomics firm Nabsys has completed ... Barrett Bready , M.D., who returned to the ... original technical leadership team, including Chief Technology Officer, ... Development, Steve Nurnberg and Vice President of Software and ... company. Dr. Bready served as CEO of ...
Breaking Biology News(10 mins):